Autolus announces update on AUTO4 and AUTO5 programmes

LONDON, 3 December 2018: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation notes its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL) (“Autolus”), announced that the first patient has been dosed in its Phase 1/2 LibrA T1 clinical trial of AUTO4, a developmental therapy for the treatment of relapsed or refractory TRBC1-positive peripheral T cell lymphoma (PTCL). In addition, Autolus also announced that data on its preclinical sister programme, AUTO5 targeting TRBC2-positive lymphoma, were presented at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...